Insider Transactions in Q3 2022 at Tracon Pharmaceuticals, Inc. (TCON)
Insider Transaction List (Q3 2022)
Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Sep 29
2022
|
Opaleye Management Inc. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
9,400
+2.24%
|
$9,400
$1.74 P/Share
|
Sep 27
2022
|
Opaleye Management Inc. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
1,700
+0.42%
|
$1,700
$1.69 P/Share
|
Sep 22
2022
|
Charles Theuer PRESIDENT AND CEO |
BUY
Open market or private purchase
|
Direct |
5,000
+1.83%
|
$5,000
$1.76 P/Share
|
Sep 22
2022
|
Opaleye Management Inc. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
17,311
+1.73%
|
$17,311
$1.73 P/Share
|
Sep 20
2022
|
Opaleye Management Inc. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
10,000
+2.53%
|
$10,000
$1.85 P/Share
|
Sep 19
2022
|
Opaleye Management Inc. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
5,000
+1.32%
|
$5,000
$1.87 P/Share
|
Sep 12
2022
|
Scott B. Brown CHIEF FINANCIAL OFFICER |
BUY
Open market or private purchase
|
Direct |
2,500
+14.6%
|
$5,000
$2.02 P/Share
|
Jul 26
2022
|
Opaleye Management Inc. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
2,254
+0.61%
|
$2,254
$1.72 P/Share
|
Jul 22
2022
|
Charles Theuer PRESIDENT AND CEO |
BUY
Open market or private purchase
|
Direct |
4,500
+1.69%
|
$4,500
$1.85 P/Share
|
Jul 15
2022
|
Opaleye Management Inc. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
11,826
+3.12%
|
$11,826
$1.78 P/Share
|
Jul 14
2022
|
Opaleye Management Inc. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
7,187
+1.98%
|
$7,187
$1.81 P/Share
|
Jul 13
2022
|
Charles Theuer PRESIDENT AND CEO |
BUY
Open market or private purchase
|
Direct |
3,000
+1.15%
|
$3,000
$1.84 P/Share
|
Jul 12
2022
|
Charles Theuer PRESIDENT AND CEO |
BUY
Open market or private purchase
|
Direct |
3,000
+1.16%
|
$3,000
$1.87 P/Share
|